Clinical trials: Tumor Pancreas
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00227617
- Testing
- bevacizumab, 5-fluorouracil, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities
Pancreatic cancer is the 5th leading cause of cancer death and the worst prognostic cancer in the world. This is due to high recurrent rate after surgical resection and poor response to chemotherapy and radiotherapy.
- Trial name
- NCT02887599
- Testing
- Blood collection
- Where
- South Korea
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Pancreatic Cancer, EUS-FNB
Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
The goal of this observational study is to use endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) to investigate the intratumoral microbiome profile in patients with pancreatic ductal adenocarcinoma (PDAC) and to evaluate…
- Conditions
- Pancreatic Cancer, EUS-FNB, Intratumoral Microbiota, Diagnosis
- Trial name
- NCT06655233
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Gastrointestinal Cancer
The Status of Immune Checkpoints at Gastrointestinal Cancer
Colorectal cancers are the third most common cancer in the world. In advanced stages of colorectal cancers, peritoneal carcinomatosis and intraabdominal acid development occur.
- Trial name
- NCT04566848
- Testing
- Flow cytometric analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul Training and Research Hospital
Pancreatic Cancer, Metastatic Pancreatic Cancer
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
- Trial name
- NCT04133155
- Testing
- nab paclitaxel plus gemcitabine
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using survival time.
- Trial name
- GEST (NCT00498225)
- Testing
- Gemcitabine plus TS-1, TS-1, Gemcitabine
- Where
- 12 sites in Japan, Taiwan
- Volunteers
- 834 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
Tumor metastasis and invasion are the leading causes of cancer-related deaths, with over 90% of cancer patients dying from distant metastasis.
- Trial name
- NCT07331532
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
Serum Uric Acid
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
- Trial name
- NCT07091526
- Testing
- serum uric acid test
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Pancreatic Cancer
Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer
RATIONALE: New diagnostic procedures, such as laparoscopic ultrasound, may improve the ability to detect pancreatic cancer and determine the extent of disease.
- Trial name
- NCT00003085
- Testing
- laparoscopy, ultrasound imaging
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Southern California
Pancreatic Neoplasms, Metastases, Neoplasm
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas.
- Trial name
- NCT00035035
- Testing
- GEMZAR, ALIMTA
- Where
- 114 sites in United States, Argentina and 16 more
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer, Gastric Cancer
COVID - 19 and Advanced Gastro-intestinal Cancer Treatment
A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Esophagus Cancer, Colorectal Cancer
- Trial name
- COVID - AGICT (NCT04686747)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- S.M. Misericordia Hospital
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Carcinoma, Pancreatic Ductal
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Pancreatic cancer represents the most lethal of the common malignancies with a 5-year survival rate of less than 5%. For patients who are eligible for potentially curative resection, despite mortality and morbidity rates after…
- Trial name
- NCT03403101
- Testing
- S1, Oxaliplatin, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Gastric Cancer, Gastroesophageal Junction Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06921928
- Testing
- AZD4360
- Where
- 14 sites in United States, China and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Pancreas Cancer, Adenocarcinoma of the Pancreas
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.
- Conditions
- Pancreas Cancer, Adenocarcinoma of the Pancreas, Pancreatic Cancer, Tumor of Pancreas
- Trial name
- GANNON (NCT06282809)
- Testing
- HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- HistoSonics, Inc.
Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Colon
Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours
Reflexion on the therapeutic strategies to implement in patients at the end of life is advancing rapidly in France. However, beyond the choices presented to patients, sometimes even the decision to carry on, to limit or to stop…
- Conditions
- Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Colon, Non-resectable Metastatic Cancer of the Rectosigmoid Junction, Non-resectable Metastatic Cancer of the Stomach
- Trial name
- EOLE (NCT03328065)
- Testing
- Interviews, Questionnaires
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Breast Cancer, Colorectal Cancer
Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer
A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to…
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Adenocarcinoma, Pancreatic Cancer
- Trial name
- WATCH AND ACT (NCT07429487)
- Testing
- APA program
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Antoine Lacassagne
Metastatic Pancreatic Cancer, Pancreatic Cancer
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior…
- Trial name
- PANCRIT®-1 (NCT01956812)
- Testing
- IMMU-107, Gemcitabine
- Where
- 64 sites in United States, Austria and 6 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.